
It is made available under a CC-BY-ND 4.0 International license .

Graphical Abstract



It is made available under a CC-BY-ND 4.0 International license .

Phenome-wide causal proteomics enhance systemic lupus erythematosus flare prediction: A study in Asian populations

Liying Chen^a, Ou Deng^c, Ting Fang^a, Mei Chen^a, Xvfeng Zhang^a, Ruichen Cong^c, Dingqi Lu^b, Runrun Zhang^b, Qun Jin^c, Xinchang Wang^b,

 ^aSecond Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China
 ^bDepartment of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China
 ^cGraduate School of Human Sciences, Waseda University, Mikajima, Tokorozawa, 359-1192, Japan

Abstract

Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by unpredictable flares. This study aimed to develop a novel proteomics-based risk prediction model specifically for Asian SLE populations to enhance personalized disease management and early intervention. **Methods**: A longitudinal cohort study was conducted over 48 weeks, including 139 SLE patients monitored every 12 weeks. Patients were classified into flare (n = 53) and non-flare (n = 86) groups. Baseline plasma samples underwent data-independent acquisition (DIA) proteomics analysis, and phenome-wide Mendelian randomization (PheWAS) was performed to evaluate causal relationships between proteins and clinical predictors. Logistic regression (LR) and random forest (RF) models were used to integrate proteomic and clinical data for flare risk prediction.

Results: Five proteins (SAA1, B4GALT5, GIT2, NAA15, and RPIA) were significantly associated with SLE Disease Activity Index-2K (SLEDAI-2K) scores and 1-year flare risk, implicating key pathways such as B-cell receptor

Corresponding author: Xinchang Wang, Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, No.318, Chaowang Road, Gongshu District, Hangzhou, Zhejiang Province, China. Email: 20054007@zcmu.edu.cn; ossani@126.com

It is made available under a CC-BY-ND 4.0 International license .

signaling and platelet degranulation. SAA1 demonstrated causal effects on flare-related clinical markers, including hemoglobin and red blood cell counts. A combined model integrating clinical and proteomic data achieved the highest predictive accuracy (AUC = 0.769), surpassing individual models. SAA1 was highlighted as a priority biomarker for rapid flare discrimination.

Conclusion: The integration of proteomic and clinical data significantly improves flare prediction in Asian SLE patients. The identification of key proteins and their causal relationships with flare-related clinical markers provides valuable insights for proactive SLE management and personalized therapeutic approaches.

Keywords: Systemic lupus erythematosus, Flare, Causal proteomics, Phenome-wide mendelian randomization, Longitudinal cohort study

1 Introduction

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder
characterized by the production of multiple autoantibodies and involvement
of various organ systems. Its clinical course is unpredictable, with patients
experiencing remissions and flares sudden increases in disease activity that
pose significant management challenges[1, 2]. Although early disease control
and adherence to pharmacological interventions are foundational in managing
SLE, conventional predictive models relying on clinical observations and genetic markers are limited in capturing the disease's dynamic and multifactorial
nature[3, 4].

The complexity of SLE flares, often arising unpredictably from multi-11 faceted and poorly understood triggers, necessitates a nuanced, data-driven 12 predictive approach. Accurate flare prediction requires longitudinal tracking 13 of disease activity, identification of modifiable risk factors, and comprehensive 14 evaluation of clinical, serological, and molecular markers. Recent studies in 15 Asian SLE populations have linked risk factors such as thrombocytopenia, 16 hypocomplementemia, elevated neutrophil-to-lymphocyte ratio (NLR), and 17 high platelet-to-lymphocyte ratio (PLR) to increased flare risk[5, 6]. Addi-18 tionally, the presence of specific autoantibodies like anti-ribosomal P and 19 anti-phospholipid antibodies is associated with heightened flare susceptibil-20 ity in Chinese patients [7]. Non-biological factors, including quality of life, 21 psychological stress, and overexertion, also significantly contribute to flare 22

It is made available under a CC-BY-ND 4.0 International license .

incidence, highlighting the need to consider both biological and psychosocial
variables in predictive models[8, 9, 10].

Advancements in genome-wide association studies (GWAS) and PheWAS 25 have deepened our understanding of the genetic underpinnings and phenotypic 26 expressions of autoimmune diseases. Mendelian randomization (MR) and 27 PheWAS methodologies enable exploration of causal relationships between 28 genetic variations, proteins, and disease outcomes, offering more robust 29 insights than traditional observational studies [11, 12]. Given SLE's diverse 30 nature, a multi-omics approach that integrates proteomic data with genomic 31 and clinical information is essential for identifying dynamic biomarkers capable 32 of improving flare prediction [13]. In this context, proteomics-based MR holds 33 significant promise for discovering novel, druggable protein targets, thereby 34 enhancing our ability to classify and stratify patients by flare risk. 35

This study aims to address the limitations of current predictive models 36 for SLE flares through a comprehensive, integrative approach. We first 37 conduct an exhaustive analysis of known clinical predictors to build a robust 38 baseline model. Building on this foundation, we incorporate cutting-edge 39 plasma proteomics techniques to gain deeper insights into molecular changes 40 associated with flare events. We explore causal relationships between identified 41 plasma proteins and clinical outcomes through phenome-wide Mendelian 42 randomization analyses, identifying proteins with a causal impact on flare 43 risk. Finally, we leverage advanced machine learning algorithms to integrate 44 proteomic and clinical data, constructing a predictive model that offers more 45 precise risk stratification for SLE flares. This integrative methodology aims 46 to significantly improve early detection of organ damage, guiding timely and 47 personalized therapeutic interventions. 48

49 Methods

⁵⁰ Patient Recruitment and Follow-up

This prospective multicenter study recruited 139 SLE patients between August
2020 and January 2023. Eligible participants were aged 18-65 and met the 2012
SLICC classification criteria[14]. Patients with active infections, malignancies,
or other connective tissue diseases were excluded. Disease activity was assessed
using the SLEDAI-2K at baseline and at 3, 6, and 12 months to identify flare
events.

The study was approved by the ethics committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University (approval NO.2020-KL-002-

It is made available under a CC-BY-ND 4.0 International license .

⁵⁹ IH01). Informed consent was obtained from all participants. Additional
 ⁶⁰ details are in Supplementary Table 1.

61 Outcome Measurement

⁶² The primary outcome was the occurrence of an SLE flare within 12 months, ⁶³ defined as an increase in SLEDAI-2K score by ≥ 3 points from baseline and ⁶⁴ previous assessments[15]. This widely accepted criterion standardizes flare ⁶⁵ identification.

66 Clinical Variables: Definitions and Selection

Baseline data included: (1) Complement levels (C3, C4); (2) Inflammatory 67 markers (NLR, PLR); (3) Medication use (glucocorticoids, immunosuppres-68 sants); (4) Serological markers (anti-ribosomal P antibodies); (5) Disease 69 activity (SLEDAI-2K score); and (6) Quality of life (LupusQoL questionnaire). 70 LR and RF algorithms identified key clinical predictors by ranking features 71 based on predictive importance. All variables were dichotomized (1 or 0) for 72 simplicity and clinical relevance, facilitating risk stratification. This approach 73 aims to develop a robust predictive model integrating clinical parameters 74 with proteomic biomarkers. 75

76 Proteomic Analysis

⁷⁷ DIA data were processed into spectral libraries using SpectraST and analyzed
⁷⁸ with DIA-NN (v1.7.0), ensuring accurate results. Detailed workflows are
⁷⁹ available at https://www.iprox.cn/page/HMV006.html.

⁸⁰ Differential Protein and SLEDAI-2K Correlation Analysis

Proteins expressed in at least 25% of samples were analyzed. Student's t-test identified plasma proteins differentiating flare and non-flare patients, considering proteins with $|\log_2(\text{Fold Change})| \ge 1$ and p < 0.05 as significant. Spearman's correlation assessed relationships between these proteins and SLEDAI-2K scores, with significance at p < 0.05.

86 Pathway Enrichment Analysis

 $_{\tt 87}~$ We performed pathway enrichment analysis on differentially expressed proteins

- $_{\tt 88}$ $\,$ and those correlated with SLEDAI-2K scores. We analyzed Reactome and
- ⁸⁹ KEGG pathways, considering those significantly enriched at p < 0.05 using
- 90 DAVID (https://david.ncifcrf.gov/).

It is made available under a CC-BY-ND 4.0 International license .

91 Causal Proteomics Analysis Using PheWAS

Genetic instruments for identified pQTLs were obtained from 2,958 Han Chinese participants[16]. Outcome data for SLE phenotypes were sourced from BioBank Japan (n = 179,000) and supplemented by UK Biobank and FinnGen data ($n_{\text{total}} = 628,000$)[17]. The GWAS dataset included predictors like chronic glomerulonephritis, blood cell counts, and medication use. We selected pQTLs with $p < 5 \times 10^{-8}$, independence ($R^2 < 0.001$ with clumping distance > 10,000 kb), and F statistic > 10 to ensure robust instruments.

The primary method was inverse-variance weighted Mendelian Randomization. To address potential violations, we performed sensitivity analyses using MR-Egger regression, weighted median, and mode-based estimators. Heterogeneity was assessed with Cochran's Q test, and leave-one-out analyses evaluated SNP influence on causal estimates. This approach allowed us to explore causal relationships between serum amyloid A1 (SAA1) pQTLs and SLE flare risk.

¹⁰⁶ Machine Learning-Based Biomarker Selection

We developed predictive models for SLE flares using LR and RF algorithms. Three models were created: (1) Clinical models using validated risk parameters; (2) Protein models using identified biomarkers; and (3) Combined models integrating clinical and proteomic data. Datasets were split into training (85%) and testing (15%) sets. Model performance was evaluated using Receiver Operating Characteristic curves and calibration curves to assess discriminative ability and reliability.

114 Statistical Analysis

Statistical analyses were conducted using R (v4.3.2) and GraphPad Prism
8. Clinical data are presented as medians with interquartile ranges. Group
comparisons used Student's t-test. Correlation analyses and linear regression
assessed variable relationships. PheWAS analyses employed the TwoSampleMR
R package. Predictive models used LR. Model accuracy was assessed using
ROC curves and Area Under the Curve metrics via the pROC R package.

121 Results

- 122 Clinical Data Characteristics and Flare Outcome
- As shown in Fig.1, 139 SLE patients were monitored over 48 weeks and classified into flare (n = 53) and non-flare (n = 86) groups; 38% experienced

It is made available under a CC-BY-ND 4.0 International license .

at least one flare. The flare group had a high female predominance (94%), aligning with SLE's gender disparity. Approximately 47% of flare patients were positive for anti-dsDNA antibodies. Significantly, the flare group had a higher prevalence of rRNP antibodies than the non-flare group (p = 0.019), suggesting their potential role in predicting flares.

Significant differences in erythrocyte sedimentation rate (ERY, p = 0.008), 130 platelet count (PLT, p = 0.023), and platelet-to-lymphocyte ratio (PLR, 131 p = 0.035) were observed, highlighting their potential as flare risk markers. 132 Medication use showed no significant difference in prednisone use (p = 0.284). 133 Hydroxychloroquine use was slightly lower in the flare group (by 11%), though 134 not statistically significant (p = 0.617), warranting further investigation into 135 its protective effects. No significant differences in organ involvement were 136 observed (p > 0.05). Baseline characteristics are detailed in Table1. 137

¹³⁸ Importance Ranking of Clinical Predictors

We identified key clinical risk factors for SLE flares using univariate LR and RF based on 39 baseline features from 139 patients. In the LR model (Fig.2A), top predictors were: (1) 24-hour urinary total protein (UTP), (2) urinary erythrocyte count (ERY), (3) platelet count (PLT), (4) platelet-tolymphocyte ratio (PLR), and (5) anti-ribonucleoprotein (rRNP) antibodies. The RF model (Fig.2B) yielded a similar ranking, with NLR as the fifth predictor.

146 Identification of Differentially Expressed Biomarkers Associated with Flare

Proteomic analysis identified 102 significantly differentially expressed proteins (73 upregulated, 23 downregulated) associated with flares (Fig.3A), based on proteins detected in over 25% of samples. A heatmap (Fig.3B) illustrates these findings. Pathway enrichment analysis using Reactome revealed involvement in key pathways: (1) B-cell receptor (BCR) downstream signaling, (2) response to elevated platelet cytosolic Ca²⁺, and (3) platelet degranulation (Fig.3C), offering insights into molecular mechanisms underlying flares.

¹⁵⁴ Proteins Significantly Associated with SLEDAI-2K

¹⁵⁵ We identified plasma proteins significantly associated with SLEDAI-2K ¹⁵⁶ scores. KEGG pathway analysis indicated their involvement in neurode-¹⁵⁷ generation, lipid metabolism, atherosclerosis, and neurotrophin signaling ¹⁵⁸ (Fig.3D). Protein-protein interaction analysis using STRING (Fig.3E) showed

It is made available under a CC-BY-ND 4.0 International license .

functional relationships among these proteins. Among 13 proteins cor-159 relating with SLEDAI-2K, five were significantly upregulated and posi-160 tively associated with worse outcomes: (1) Serum Amyloid A-1 (SAA1), 161 (2) β -1,4-galactosyltransferase 5 (B4GALT5), (3) Ribose 5-phosphate Iso-162 merase A (RPIA), (4) GTPase-activating Protein 2 (GIT2), and (5) N-163 alpha-acetyltransferase 15 (NAA15). Correlation analysis (Fig.3F) showed 164 significant positive associations between SAA1 and B4GALT5, RPIA, and 165 NAA15, suggesting potential functional relationships in SLE activity and 166 flare risk. 167

¹⁶⁸ Causal Effects of Flare-Associated Proteins on SLE and Risk Factors

Using PheWAS, we investigated causal mechanisms between plasma proteins 169 and SLE flares, focusing on pQTLs for SAA1. We examined 220 SLE-related 170 outcomes using data from BioBank Japan. Six SNPs associated with SAA1 171 levels were identified as instrumental variables. Inverse-variance weighted 172 (IVW) analysis revealed significant causal effects of SAA1 on four flare-related 173 outcomes (OR = 1.071, 95% CI: 1.004 - 1.143, p = 0.040), hemoglobin (OR= 174 0.971, 95% CI: 0.947 - 0.996, p = 0.023, red blood cell count (OR = 0.971, 175 95% CI: 0.947 - 0.996, p = 0.021), hematocrit (OR = 0.967, 95% CI: 0.937 176 -0.997, p = 0.031) (Fig.4A-D, Table 2). All of them exhibited absence of 177 heterogeneity by IVW (Cochran's Q = 0.419; Cochran's Q = 0.263; Cochran's 178 Q = 0.291; Cochran's Q = 0.104, respectively) and MR-Egger (Cochran's 170 Q = 0.334; Cochran's Q = 0.169; Cochran's Q = 0.195; Cochran's Q = 0.068, 180 respectively), horizontal pleiotropy by MR-Egger (intercept = -0.015, p= 181 0.585; intercept = -0.001, p = 0.891; intercept = -0.003, p = 0.808; intercept 182 = -0.005, p = 0.694, respectively). The leave-one-out method suggested that 183 the MR analysis results were reliable (Fig.5A-D). 184

¹⁸⁵ Construction and Internal Validation of Flare Risk Prediction Models

We developed predictive models for SLE flare risk by dividing patients into
training and test sets. Using LR and random forest algorithms, and following
TRIPOD guidelines[18], we selected six key clinical variables: UTP, ERY,
PLT, PLR, anti-rRNP antibodies, and NLR.

Three models were developed: a clinical model, a protein-based model using five key proteins (SAA1, B4GALT5, GIT2, NAA15, RPIA), and a combined model integrating clinical and proteomic variables. ROC curve analysis showed the protein-based model had superior predictive accuracy (AUC = 0.744, 95% CI: 0.646 - 0.842) compared to the clinical model (AUC =

¹⁹⁵ 0.643, 95% CI: 0.541 - 0.745). The combined model achieved the highest AUC ¹⁹⁶ (AUC = 0.769, 95% CI : 0.678 - 0.860), indicating the benefit of integrating ¹⁹⁷ clinical and proteomic data.

¹⁹⁸ Calibration analysis demonstrated good predictive performance for all ¹⁹⁹ models (Fig.6A-C). The protein-based model showed particular strength ²⁰⁰ in AUC and Mean Absolute Error (MAE), suggesting its suitability for ²⁰¹ independent flare prediction. The combined model may be more appropriate ²⁰² in complex clinical scenarios requiring multiple variables for accurate risk ²⁰³ assessment.

204 Discussion

This is the first study to develop an SLE flare prediction model based on proteomic analysis in an East Asian population. We identified novel molecular pathways and biomarkers associated with SLE flares, offering valuable insights for improved risk stratification and personalized management.

Pathway enrichment analysis showed significant involvement of B cell 209 receptor signaling, elevated platelet cytosolic Ca^{2+} responses, and platelet 210 degranulation in SLE flare pathogenesis. KEGG analysis revealed enrichment 211 of neurodegeneration, lipid metabolism, atherosclerosis, and neurotrophin 212 signaling pathways among proteins linked to disease activity. These find-213 ings highlight the complex interplay between immune activation, vascular 214 responses, and systemic inflammation in SLE flares, particularly affecting 215 hematological, cardiovascular, and neurological systems in this East Asian 216 cohort. 217

We identified five key proteins, SAA1, B4GALT5, GIT2, NAA15, and RPIA, strongly associated with increased SLE flare risk over 48 weeks, independent of conventional risk factors. Our analysis demonstrated a causal effect of elevated SAA1 levels on flare risk factors, underscoring its critical role in disease progression.

Integrating these proteomic biomarkers with clinical indicators significantly enhanced our model's predictive accuracy. These results confirm the prognostic potential of causal proteomics in SLE flare risk stratification, paving the way for personalized therapies and earlier interventions for high-risk patients. Previous studies support Serum Amyloid A1 (SAA1) as a key biomarker for assessing SLE flare risk, reinforcing its predictive utility. SAA1-associated

²²⁹ pQTLs have been causally linked to hematological parameters and depressive

It is made available under a CC-BY-ND 4.0 International license .

disorders in multi-GWAS PheWAS[19], enhancing our understanding of proteins in the psychological aspects of SLE flares[20]. As an acute-phase protein,
SAA1 is markedly upregulated during inflammation, contributing to organ
dysfunction[21]. Our study showed that elevated SAA1 levels causally influence hematological involvement and antirheumatic medication use, consistent
with prior findings[22].

Elevated SAA1 levels correlate with SLEDAI-2K scores and nervous system involvement severity[23]. SAA1 is linked to the Th17 cell differentiation pathway, amplifying inflammatory responses[24]. Given its pivotal role in modulating inflammatory mediators and immune cells in SLE pathophysiology[25], investigating SAA1 can advance our understanding of flare mechanisms.

Identified as an early immunological diagnostic biomarker with high sensitivity and specificity for SLE[26], SAA1 may serve as a valuable biomarker for identifying high-risk patients based on our East Asian PheWAS results. These findings suggest potential therapeutic targets for personalized treatments. However, since infections also trigger flares and SAA1 is associated with white blood cell count and NLR, further research is needed to distinguish SLE flares from infection-related events[27].

 β -1,4-Galactosyltransferase V (B4GALT5) is crucial in carbohydrate metabolism, specifically in lactosylceramide synthesis [28]. Unexpectedly, our logistic regression showed a strong positive correlation between B4GALT5 expression and SLE flares, making it a significant protein associated with flare risk. Given B4GALT5's role in antiviral immunity, overexpression leads to upregulation of inflammatory cytokines and glycosylated surface proteins involved in antigen presentation, cell adhesion, and migration[29].

However, we did not establish a causal relationship between B4GALT5 and 255 SLE, possibly due to the low prevalence of B4GALT5 variants in the East Asian 256 population studied. This underscores the need for diverse population studies 257 to evaluate B4GALT5's role in SLE pathogenesis and its predictive value. The 258 unexpected correlation suggests a complex interplay between glycosylation 259 processes, immune responses, and SLE activity. Further investigation is needed 260 to elucidate how B4GALT5 might influence flare risk, given its functions 261 in carbohydrate metabolism and immune regulation. These findings open 262 avenues for understanding the glycosylation-immune axis in SLE and potential 263 therapeutic interventions. 264

GIT2 and NAA15 emerged as potential contributors to SLE flares. GIT2 is a scaffold protein regulating aging processes affecting multiple tissues and linked to neurodegeneration and cardiovascular disorders[30]. NAA15

It is made available under a CC-BY-ND 4.0 International license .

is a susceptibility gene for neurodevelopmental disorders[31], implicated in
congenital cardiac anomalies, plaque stability in atherosclerosis, and seizure
pathophysiology[32, 33]. Although no direct evidence links GIT2 and NAA15
to SLE, their identification suggests novel pathways in SLE pathogenesis.
Further research is needed to elucidate their specific roles in SLE flares,
particularly considering disease duration and age, which merit attention in
risk prediction models.

SLE progression involves distinct risk factors at different disease stages. 275 Early organ damage is driven by active disease (reflected in SLEDAI-2K), while 276 later damage results from long-term medication effects, especially prolonged 277 glucocorticoid use and withdrawal[34, 35, 36]. We identified key clinical 278 risk factors for flares, including hematological and renal involvement and 279 medication use, aligning with traditional findings. Risk factors may shift 280 during disease progression, with early damage from disease activity and later 281 damage from drug side effects, notably glucocorticoid therapy. 282

Traditional correlation studies offer insights but do not establish causality. We employed proteomic Mendelian randomization to develop robust flare prediction models. By integrating correlational methods with advanced machine learning and causal analyses, we aimed to enhance prediction accuracy. Identifying proteomic biomarkers with direct causal effects provides deeper insights into SLE flare mechanisms, highlighting potential causal pathways and therapeutic targets for future interventions.

This study has several limitations. The small sample size and focus on 290 an East Asian population may limit statistical power and generalizability to 291 broader populations. The 12-month follow-up may be insufficient to capture 292 long-term fluctuations in SLE disease activity. Moreover, reliance on advanced 293 proteomics techniques, while valuable, may hinder clinical accessibility and 294 routine implementation. Although our PheWAS analysis revealed associations 295 between genetic protein levels and SLE, establishing definitive causality 296 remains challenging due to the complexities of SLE and potential violations 297 of Mendelian randomization assumptions. Therefore, these results should be 298 interpreted with caution. Future research should prioritize external validation 299 of our predictive model in diverse cohorts, adhering to the TRIPOD guidelines. 300 Studies with larger, heterogeneous populations and extended follow-up periods 301 are essential to address current limitations. Developing methodologies that 302 account for time-varying exposures and non-linear associations will enhance 303 model robustness and accuracy. Further investigation is needed to verify 304 causal relationships between identified proteins and SLE risk, improving 305

It is made available under a CC-BY-ND 4.0 International license .

clinical applicability. Additionally, comprehensive proteomic analyses across
 multiple organs are necessary to assess organ-specific protein effects, providing
 deeper insights into early flare mechanisms.

309 Conclusion

This study demonstrates the potential of integrating causal proteomics with 310 clinical risk factors to improve SLE flare prediction. Our findings provide 311 significant advancements in understanding the molecular mechanisms under-312 lying SLE flares and offer a foundation for more precise and personalized 313 approaches to SLE management. The identified proteomic signatures and 314 causal pathways represent promising avenues for future therapeutic interven-315 tions and risk stratification strategies, with the potential to enhance patient 316 care and outcomes in SLE. 317

318 Abbreviations:

- 319 SLE: systemic lupus erythematosus;
- 320 PheWAS: phenome-wide mendelian randomization;
- 321 GWAS: genome-wide association studies;
- 322 MR: mendelian randomization;
- 323 DIA: data-independent acquisition;
- 324 LR: logistic regression;
- 325 RF: random forest;
- 326 UTP: 24-hour urinary total protein;
- 327 ERY: urinary erythrocyte count;
- 328 PLT: platelet count;
- 329 NLR: neutrophil-to-lymphocyte ratio;
- 330 PLR: platelet-to-lymphocyte ratio;
- 331 rRNP: anti-ribosomal P antibodies;
- 332 LupusQoL: lupus quality of life;
- 333 SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000;
- 334 BCR: B-cell receptor;
- 335 SLICC: systemic lupus international collaborating clinics;
- 336 KEGG: Kyoto Encyclopedia of Genes and Genomes;
- 337 SAA1: serum amyloid A1;
- 338 B4GALT5: $\beta 1,4$ -galactosyltransferase 5;
- 339 RPIA: Ribose 5-phosphate isomerase A;
- 340 GIT2: GTPase-activating protein 2;

- 341 NAA15: N-alpha-acetyltransferase 15;
- 342 IVW: inverse-variance weighted;
- 343 TRIPOD: transparent reporting of a multivariable prediction model for individual prognosis
- 344 or diagnosis.

It is made available under a CC-BY-ND 4.0 International license .

Number of patients	Total $(n = 139)$	Dhic characteristics of SLE flare. Primary outcome: 1-year flare				
		Non-flare $(n = 86)$	Flare $(n = 53)$	Р		
Sex, n (%)	130 (94%)	80 (93%)	50 (94%)	1		
Age, Median (Q1, Q3)	36(28.5, 48.5)	34 (31, 42.75)	40 (28, 51)	0.357		
Course, Median (Q1, Q3)	6(3, 12)	6(3, 12)	6(3, 11)	0.617		
SLE_DAI, Median (Q1, Q3)	6(3, 8)	6(3, 8)	6(4, 12)	0.337		
dsDNA, n (%)	66 (47%)	41 (48%)	25 (47%)	1		
Sm, n (%)	35 (25%)	19 (22%)	16 (30%)	0.386		
SSA, n (%)	62 (45%)	37 (43%)	25 (47%)	0.763		
Ro52, n (%)	52 (37%)	28 (33%)	24 (45%)	0.185		
SSB, n (%)	22 (16%)	12 (14%)	10 (19%)	0.595		
rRNP, n (%)	38 (27%)	17 (20%)	21 (40%)	0.019		
Scl70, n (%)	1 (1%)	0 (0%)	1 (2%)	0.381		
AHA, n (%)	27 (19%)	17 (20%)	10 (19%)	1		
AnuA, n (%)	39 (28%)	24 (28%)	15 (28%)	1		
CENP, n (%)	2(1%)	0 (0%)	2 (4%)	0.144		
AMA_M2, n (%)	2(1%)	1 (1%)	1 (2%)	1		
U10RNP, n (%)	25 (18%)	15 (17%)	10 (19%)	1		
pro, n (%)	48 (34%)	27 (31%)	21 (40%)	0.492		
ERY, Median (M25, M75)	3(0, 13)	2.4(0, 10.6)	5.5(1, 20)	0.008		
LEU, Median (M25, M75)	6(2, 24.8)	6(1, 24.45)	8 (2.3, 26)	0.333		
UTP, Median (M25, M75)	102.45 (102.45, 180)	102.45(102.45, 102.45)	180 (180, 180)	< 0.001		
WBC, Median (M25, M75)	5.2(4.3, 6.86)	5.2(4.27, 6.9)	5.1(4.4, 6.4)	0.873		
NEUT, Median (M25, M75)	3.43(2.46, 4.82)	3.46(2.5, 4.78)	3.33(2.28, 4.88)	0.714		
LYM, Median (M25, M75)	1.36(1.04, 1.97)	1.33(1.03, 1.88)	1.43(1.04, 2.23)	0.534		
PLT, Median (M25, M75)	208 (157, 248.5)	217 (172.5, 258.75)	175.5 (138, 225)	0.023		
PLR, Median (M25, M75) 1	45.37 (102.39, 190.67)	156.1 (111.63, 200.63)	134.18 (83.08, 179.71)	0.035		
NLR, Median (M25, M75)	2.36(1.62, 3.51)	2.37(1.79, 3.48)	2.25(1.51, 3.54)	0.411		
C3, Median (M25, M75)	0.76 (0.66, 0.9)	0.74(0.66, 0.9)	$0.78 \ (0.67, \ 0.93)$	0.606		
C4, Median (M25, M75)	0.15(0.11, 0.2)	0.15(0.11, 0.2)	0.15(0.1, 0.2)	0.776		
lupusQoL, Median (M25, M75)	114(101, 121)	114 (103.25, 120.75)	110 (97, 122)	0.529		
Prednisone, Median (M25, M75)	10(5, 15)	7.5 (5, 15)	10(5, 15)	0.284		
Hydroxychloroquine, n (%)	86 (62%)	57 (66%)	47 (55%)	0.617		
Immunosuppressant, n (%)	90 (65%)	57 (66%)	33 (62%)	0.765		
Noninvolved, n (%)	31 (22%)	17 (20%)	14 (26%)	0.481		
Multisystem, n (%)	40 (29%)	27 (31%)	13 (25%)	0.499		
Hematologic, n (%)	22 (16%)	15 (17%)	7 (13%)	0.671		
Neuropsychiatric, n (%)	7 (5%)	3 (3%)	4 (8%)	0.427		
Mucocutaneous, n (%)	62 (45%)	36 (42%)	26 (49%)	0.514		
Renal, n (%)	57 (41%)	39 (45%)	18 (34%)	0.251		

Table 1: Clinical and demographic characteristics of SLE flare.

Table 2: Mendelian Randomization Results - Causal Effects Between pQTLs and SLEFlare Risk (IVW Approach)

	NI GNID	0	G. L LE		
Outcome	N SNP	β	Standard Error	p	OR $(95\% \text{ CI})$
Hemoglobin	6	-0.029	0.013	0.023	$0.971 \ (0.947, \ 0.996)$
Hematocrit	6	-0.034	0.016	0.031	$0.967 \ (0.937, \ 0.997)$
Red blood cell count	6	-0.029	0.013	0.021	$0.971 \ (0.947, \ 0.996)$
Anti-inflammatory medication	6	0.069	0.033	0.040	$1.071 \ (1.004, \ 1.143)$
Note: Source by Zhena Lab					

Note: Source by Zheng Lab.

It is made available under a CC-BY-ND 4.0 International license .

345




Figure 1: Study design and patient follow-up schema. Schematic representation of the recruitment process, inclusion and exclusion criteria, and longitudinal assessment timeline for SLE patients over the 48-week study period.




Figure 2: Comparative analysis of clinical variable importance in predicting SLE flares. (A) Ranking of clinical variables based on LR coefficients. (B) Relative importance of clinical variables determined by the RF algorithm, measured by the mean decrease in Gini impurity.




Figure 3: Multi-dimensional proteomic profiling of SLE flares. (A) Volcano plot illustrating the distribution and statistical significance of 102 differentially expressed proteins between flare and non-flare groups ('the absolute value of the base-2 logarithm of the fold change' ≥ 1 , p < 0.05). (B) Hierarchical clustering heatmap displaying normalized plasma protein expression levels, with a color gradient (blue to red) representing relative protein abundance. (C) Reactome pathway enrichment analysis of flare-associated proteins, with statistical significance indicated by -log10(p-value). (D) KEGG pathway analysis of proteins correlated with SLEDAI-2K scores. (E) STRING-based protein-protein interaction network of SLEDAI-2K-associated proteins, where node size reflects the degree of interaction. (F) Correlation matrix showing the relationships between upregulated proteins positively associated with SLEDAI-2K scores.




Figure 4: Mendelian randomization analysis of SAA1's causal effects on SLE flare risk factors. Forest plots from random-effects inverse-variance weighted (IVW) analyses depicting the genetic causal relationships between SAA1 and (A) anti-inflammatory and antirheumatic medication use, (B) hemoglobin levels, (C) red blood cell count, and (D) hematocrit. Odds ratios and 95% confidence intervals are shown.




Figure 5: Sensitivity analysis of Mendelian randomization results using the leave-one-out method. (A) Anti-inflammatory and antirheumatic medication use. (B) Hemoglobin levels. (C) Red blood cell count. (D) Hematocrit. This analysis evaluates the robustness of the causal relationships between SAA1 and four key outcomes: anti-inflammatory and antirheumatic medication use, hemoglobin levels, red blood cell count, and hematocrit. Each subplot (A-D) represents one of these outcomes, with individual points showing the Mendelian randomization estimate after excluding one SNP from the analysis, while the vertical line indicates the estimate using all SNPs. This approach helps identify potential outlier SNPs that may disproportionately influence the overall results.




Figure 6: Comparative performance evaluation of SLE flare risk prediction models. (A-C) Receiver Operating Characteristic (ROC) curves (left) and calibration plots (right) for (A) clinical, (B) proteomic, and (C) combined prediction models. ROC curves display sensitivity versus 1-specificity, with Area Under the Curve (AUC) values indicated. Calibration plots show predicted versus observed probabilities, generated using 1,000 bootstrap resamples. Hosmer-Lemeshow goodness-of-fit test P-values are provided to evaluate model calibration.

It is made available under a CC-BY-ND 4.0 International license .

346 Supplementary Tables

347 1. Name of multi-center hospitals

Table S1. Name of multi-center hospitals					
The Second Affiliated Hospital of Zhejiang Chinese Medical University					
Guang'anmen Hospital China Academy of Chinese Medical Sciences					
Chinese People's Liberation Army General Hospital					
The First Affiliated Hospital of Guangzhou University of Chinese					
Medicine					
Shenzhen Futian Hospital for Rheumatic Diseases					
The First Affiliated Hospital of Henan University of CM					
First Teaching Hospital of Tianjin University of Traditional Chinese					
Medicine					
The First School of Clinical Medicine Yunnan University of Chinese					
Medicine					
Department of Rheumatology Second Affiliated Hospital of Zhejiang					
University					
The Affiliated Hospital of Medical School Ningbo University					
The Second Affiliated Hospital of Jiaxing University					
Department of Rheumatology Huzhou Hospital of Traditional Chinese					
Medicine Affiliated to Zhejiang Chinese Medical University					
Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing TCM					
Hospital Affiliated to Zhejiang Chinese Medical University					

It is made available under a CC-BY-ND 4.0 International license .

348 Acknowledgments

We thank members of the Genomics Platform (Human Phenome Institute, Fudan University) for library preparation experiments and providing the proteomics analysis. We also appreciate the medical background advice provided by Professor Atsushi Ogihara of Waseda University.

353 Authors' Contributions

LC conceptualized the study, developed the methodology, conducted formal 354 analysis, and led the writing of the manuscript. OD contributed to the 355 development of the methodology, analysis, supervision, and revision of the 356 manuscript. TF, MC, and XZ were involved in data collection, curation, and 357 validation. RC, DL, and RZ provided assistance in manuscript preparation 358 and revision. QJ contributed to conceptualization, supervision, and project 359 administration. XW oversaw the project, providing leadership in conceptual-360 ization, supervision, funding acquisition, and manuscript review. All authors 361 have reviewed and approved the final version of the manuscript. 362

363 Funding

This research was supported by the Zhejiang Traditional Chinese Medical Modernization Special Project (grant number 2020ZX008).

366 Data Availability

The mass spectrometry proteomics data generated in this study have been deposited in the Integrated Proteome Resources (iProX) database under the dataset identifier IPX0007978000. The data are publicly accessible through the iProX website (https://www.iprox.cn/page/). Additional datasets that support the findings of this study are available from the corresponding author upon reasonable request.

373 Declarations

374 Ethics approval and consent to participate

³⁷⁵ The study was approved by the ethics committee of the Second Affiliated 58

³⁷⁶ Hospital of Zhejiang Chinese Medical University (approval NO.2020-KL-002-

³⁷⁷ 59 IH01). Informed consent was obtained from all participants.

It is made available under a CC-BY-ND 4.0 International license .

378 Consent for publication

Not applicable. Our manuscript does not contain any individual person's
data.

- 381 Competing Interests
- ³⁸² The authors declare no competing interests.

It is made available under a CC-BY-ND 4.0 International license .

383 References

- [1] Guidelines for referral and management of systemic lupus erythematosus
 in adults. American College of Rheumatology Ad Hoc Committee on
 Systemic Lupus Erythematosus Guidelines. Arthritis and rheumatism.
 1999;42(9):1785-96.
- [2] Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis
 JN, et al. 2019 update of the EULAR recommendations for the manage ment of systemic lupus erythematosus. Annals of the rheumatic diseases.
 2019;78(6):736-45.
- [3] Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska
 Z, Martorell-Marugán J, et al. Integrative Analysis Reveals a Molecular
 Stratification of Systemic Autoimmune Diseases. Arthritis & rheumatology (Hoboken, NJ). 2021;73(6):1073-85.
- [4] Goetz I, Choong C, Winnie J, Nelson DR, Birt J, Noxon V, et al. Develop ment of a claims-based flare algorithm for systemic lupus erythematosus.
 Current medical research and opinion. 2022;38(9):1641-9.
- [5] Cho J, Lahiri M, Teoh LK, Dhanasekaran P, Cheung PP, Lateef A.
 Predicting flares in patients with stable systemic lupus erythematosus.
 Seminars in arthritis and rheumatism. 2019;49(1):91-7.
- [6] Cho J, Liang S, Lim SHH, Lateef A, Tay SH, Mak A. Neutrophil to
 lymphocyte ratio and platelet to lymphocyte ratio reflect disease activity
 and flares in patients with systemic lupus erythematosus-A prospective
 study. Joint bone spine. 2022;89(4):105342.
- [7] Sun F, Zhao L, Wang H, Zhang D, Chen J, Wang X, et al. Risk factors
 of disease flares in a Chinese lupus cohort with low-grade disease activity.
 Lupus science & medicine. 2022;9(1).
- [8] Goldschen L, Ellrodt J, Amonoo HL, Feldman CH, Case SM, Koenen KC, et al. The link between post-traumatic stress disorder and systemic lupus erythematosus. Brain, behavior, and immunity. 2023;108:292-301.
- [9] Yelin E, Trupin L, Bunde J, Yazdany J. Poverty, Neighborhoods, Persistent Stress, and Systemic Lupus Erythematosus Outcomes: A Qualitative Study of the Patients' Perspective. Arthritis care & research.
 2019;71(3):398-405.

- [10] Katz P, Wan GJ, Daly P, Topf L, Connolly-Strong E, Bostic R, et al.
 Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2020;29(12):3251-61.
- [11] Yuan S, Jiang F, Chen J, Lebwohl B, Green PHR, Leffler D, et al.
 Phenome-wide Mendelian randomization analysis reveals multiple health
 comorbidities of coeliac disease. EBioMedicine. 2024;101:105033.
- Yuan S, Wang L, Zhang H, Xu F, Zhou X, Yu L, et al. Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases. EBioMedicine. 2023;89:104488.
- [13] Shen X, Kellogg R, Panyard DJ, Bararpour N, Castillo KE, Lee-McMullen
 B, et al. Multi-omics microsampling for the profiling of lifestyle-associated
 changes in health. Nature biomedical engineering. 2024;8(1):11-29.
- [14] Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and rheumatism. 2012;64(8):2677-86.
- ⁴³⁴ [15] Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the
 ⁴³⁵ diagnosis and management of systemic lupus erythematosus. Annals of
 ⁴³⁶ the rheumatic diseases. 2021;80(1):14-25.
- ⁴³⁷ [16] Xu F, Yu EY, Cai X, Yue L, Jing LP, Liang X, et al. Genome-wide
 ⁴³⁸ genotype-serum proteome mapping provides insights into the cross⁴³⁹ ancestry differences in cardiometabolic disease susceptibility. Nature
 ⁴⁴⁰ communications. 2023;14(1):896.
- [17] Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S,
 et al. A cross-population atlas of genetic associations for 220 human
 phenotypes. Nature genetics. 2021;53(10):1415-24.
- [18] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting
 of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ (Clinical research ed).
 2015;350:g7594.

- [19] Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et
 al. Phenome-wide Mendelian randomization mapping the influence of the
 plasma proteome on complex diseases. Nature genetics. 2020;52(10):112231.
- [20] Moroni L, Mazzetti M, Ramirez GA, Farina N, Bozzolo EP, Guerrieri S,
 et al. Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia.
 Current rheumatology reports. 2021;23(7):52.
- [21] Rosenau BJ, Schur PH. Antibody to serum amyloid A. Journal of autoimmunity. 2004;23(2):179-82.
- [22] Márquez-Macedo SE, Perez-Arias AA, Pena-Vizcarra Ó R, Zavala-Miranda MF, Juárez-Cuevas B, Navarro-Gerrard MA, et al. Predictors of treatment outcomes in lupus nephritis with severe acute kidney injury and requirement of dialytic support. Clinical rheumatology. 2023;42(8):2115-23.
- [23] He J, Tang D, Liu D, Hong X, Ma C, Zheng F, et al. Serum proteome
 and metabolome uncover novel biomarkers for the assessment of disease activity and diagnosing of systemic lupus erythematosus. Clinical
 immunology (Orlando, Fla). 2023;251:109330.
- ⁴⁶⁷ [24] Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH, et al.
 ⁴⁶⁸ Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote ⁴⁶⁹ Inflammatory Disease. Cell. 2020;180(1):79-91.e16.
- ⁴⁷⁰ [25] Lu X, Huang Y, Zhou M, Guo Y, Zhou Y, Wang R, et al. Artesunate
 ⁴⁷¹ attenuates serum amyloid A-induced M1 macrophage differentiation
 ⁴⁷² through the promotion of PHGDH. International immunopharmacology.
 ⁴⁷³ 2024;127:111462.
- ⁴⁷⁴ [26] Zhou G, Wei P, Lan J, He Q, Guo F, Guo Y, et al. TMT-based quanti⁴⁷⁵ tative proteomics analysis and potential serum protein biomarkers for
 ⁴⁷⁶ systemic lupus erythematosus. Clinica chimica acta; international journal
 ⁴⁷⁷ of clinical chemistry. 2022;534:43-9.
- ⁴⁷⁸ [27] Luo KL, Yang YH, Lin YT, Hu YC, Yu HH, Wang LC, et al. Differential
 ⁴⁷⁹ parameters between activity flare and acute infection in pediatric patients
 ⁴⁸⁰ with systemic lupus erythematosus. Scientific reports. 2020;10(1):19913.

- ⁴⁸¹ [28] Yoshihara T, Satake H, Nishie T, Okino N, Hatta T, Otani H, et al. Lactosylceramide synthases encoded by B4galt5 and 6 genes are pivotal for neuronal generation and myelin formation in mice. PLoS genetics. 2018;14(8):e1007545.
- ⁴⁸⁵ [29] Zhang L, Ren J, Shi P, Lu D, Zhao C, Su Y, et al. The Immunological
 ⁴⁸⁶ Regulation Roles of Porcine β-1, 4 Galactosyltransferase V (B4GALT5)
 ⁴⁸⁷ in PRRSV Infection. Frontiers in cellular and infection microbiology.
 ⁴⁸⁸ 2018;8:48.
- ⁴⁸⁹ [30] van Gastel J, Boddaert J, Jushaj A, Premont RT, Luttrell LM, Janssens
 J, et al. GIT2-A keystone in ageing and age-related disease. Ageing
 ⁴⁹¹ research reviews. 2018;43:46-63.
- [31] Stessman HA, Xiong B, Coe BP, Wang T, Hoekzema K, Fenckova M, et
 al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk
 genes with autism and developmental-disability biases. Nature genetics.
 2017;49(4):515-26.
- [32] Cheng H, Dharmadhikari AV, Varland S, Ma N, Domingo D, Kleyner R,
 et al. Truncating Variants in RPIA Are Associated with Variable Levels
 of Intellectual Disability, Autism Spectrum Disorder, and Congenital
 Anomalies. American journal of human genetics. 2018;102(5):985-94.
- [33] Qun L, Wenda X, Weihong S, Jianyang M, Wei C, Fangzhou L, et al.
 miRNA-27b modulates endothelial cell angiogenesis by directly targeting
 Naa15 in atherogenesis. Atherosclerosis. 2016;254:184-92.
- [34] Ugarte-Gil MF, Alarcón GS. Low Disease Activity Early in the Course
 of Systemic Lupus Erythematosus. The Journal of rheumatology. 2024.
- Ji L, Xie W, Fasano S, Zhang Z. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. Lupus science & medicine. 2022;9(1).
- [36] Nakai T, Fukui S, Ikeda Y, Suda M, Tamaki H, Okada M. Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis. Lupus science & medicine. 2022;9(1).